Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients with metastatic non-small cell lung cancer with an ALK-positive result on an FDA-approved test. This traditional approval broadened the earlier authorization restricted by prior ALK-inhibitor exposure.
LAMPGEN ANALYSIS
Why it matters
The action converts the original accelerated approval and enables use earlier in metastatic ALK-positive disease.
What research teams should watch
Track ALK assay results and prior therapy at the date of treatment so historical cohorts match the applicable label.
PRIMARY RECORDS